EcoDrugPlus

Cytidine Deaminase

Ensembl ID : ENSOKIG00005014585
Gene Symbol: CDA
3 Cross references
150 Possible Orthologues:

Cytidine Deaminase

Ensembl ID : ENSOKIG00005000248
Gene Symbol: LOC109890140
3 Cross references
196 Possible Orthologues:

Cytidine Deaminase B

Ensembl ID : ENSOKIG00005027770
Gene Symbol: CDAB
1 Cross references
194 Possible Orthologues:

Cytochrome P450 26a1-Like

Ensembl ID : ENSOKIG00005036498
Gene Symbol: LOC109885008
3 Cross references
193 Possible Orthologues:

Cytochrome P450 26a1-Like

Ensembl ID : ENSOKIG00005040393
Gene Symbol: LOC109885008
3 Cross references
193 Possible Orthologues:

Cytochrome P450 3a27

Ensembl ID : ENSOKIG00005039199
Gene Symbol: LOC109879569
2 Cross references
522 Possible Orthologues:

Cytochrome P450 3a27-Like

Ensembl ID : ENSOKIG00005044753
Gene Symbol: LOC109879575
3 Cross references
521 Possible Orthologues:

Cytochrome P450 3a27-Like

Ensembl ID : ENSOKIG00005042050
Gene Symbol: LOC109879574
2 Cross references
520 Possible Orthologues:

Cytochrome P450 3a27-Like

Ensembl ID : ENSOKIG00005028017
Gene Symbol: LOC109879570
2 Cross references
522 Possible Orthologues:

Cytochrome P450 3a30-Like

Ensembl ID : ENSOKIG00005015407
Gene Symbol: LOC109869080
2 Cross references
443 Possible Orthologues:

Cytochrome P450 Family 19 Subfamily A Member 1

Ensembl ID : ENSOKIG00005020113
Gene Symbol: CYP19A1
3 Cross references
244 Possible Orthologues:

Cytochrome P450 Family 26 Subfamily A Member 1

Ensembl ID : ENSOKIG00005023108
Gene Symbol: CYP26A1
3 Cross references
132 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).